Determining whether SIGA Technologies (NASDAQ: SIGA) represents a buy or sell depends heavily on an investor's appetite for event-driven biodefense stocks. Because the company's financial performance relies heavily on unpredictable government procurement contracts, sporadic smallpox antiviral stockpiling orders, and global health emergency updates rather than steady commercial retail sales, equity analysts often view it as a high-risk, cyclical asset requiring rigorous fundamental tracking.